Video
Dr. Dreyling on Results for Copanlisib in Patients With B-Cell Lymphoma
Author(s):
Martin Dreyling, MD, associate professor, University of Munich, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma, during the AACR Annual Meeting.
Martin Dreyling, MD, professor of medicine, University of Munich Hospital in Grosshadern, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma, during the AACR Annual Meeting.
Although there are treatments options currently available for these patients, all of the 142 patients included in the study had already undergone at least 2 prior lines of therapy, with the majority of the patients being refractory to the previous approaches.
Surprisingly, these patients still responded to the PI3K inhibitor copanlisib, Dreyling says. In fact, there was almost a 60% response rate demonstrated in the study. In marginal zone lymphoma, the response rate was almost 70%, and the duration of the response was 22 months, Dreyling explains.
With regard to toxicity, Dreyling adds there was no major colitis observed, and elevated liver enzymes have rarely been observed.
